CompletedPhase 1NCT00720174
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Studying Angiosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Rashmi Chugh, MDUniversity of Chicago Comprehensive Cancer Center
- Intervention
- Cixutumumab(biological)
- Enrollment
- 30 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2008
Study locations (13)
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
- Ingalls Memorial Hospital, Harvey, Illinois, United States
- Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- Illinois CancerCare-Peoria, Peoria, Illinois, United States
- Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
- Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States
- University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Mercy Hospital Saint Louis, St Louis, Missouri, United States
- Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00720174 on ClinicalTrials.govOther trials for Angiosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06898970Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for AngiosarcomaVarun Monga, MBBS
- RECRUITINGPHASE2NCT07007273Pembrolizumab for Advanced Cutaneous Sarcomas Not Including AngiosarcomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06715579Cardiac Angiosarcoma International RegistryImmune Oncology Research Institute
- RECRUITINGPHASE2NCT06849986IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)Fudan University
- RECRUITINGPHASE2NCT06673628Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma PatientsNational Cancer Center, Japan
- RECRUITINGPHASE1NCT06440005A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsAngiex, Inc.
- RECRUITINGNCT06375941Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStarsItalian Sarcoma Group
- RECRUITINGNCT06541652A French Multicenter Observational Retrospective Study of Rare Primary Liver CancersFederation Francophone de Cancerologie Digestive